- Home
- FSP vs TENX Comparison
FSP vs TENX Comparison
Compare FSP & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FSP | TENX |
|---|---|---|
| Founded | 1981 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.7M | 56.2M |
| IPO Year | 2001 | 2001 |
Fundamental Metrics
Financial Performance| Metric | FSP | TENX |
|---|---|---|
| Price | $0.59 | $14.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $29.67 |
| AVG Volume (30 Days) | ★ 619.0K | 348.8K |
| Earning Date | 03-09-2026 | 03-10-2026 |
| Dividend Yield | ★ 6.84% | N/A |
| EPS Growth | ★ 15.69 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $107,162,000.00 | N/A |
| Revenue This Year | $17.91 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.56 | $4.64 |
| 52 Week High | $1.93 | $18.38 |
Technical Indicators
Market Signals| Indicator | FSP | TENX |
|---|---|---|
| Relative Strength Index (RSI) | 33.56 | 54.97 |
| Support Level | N/A | $5.99 |
| Resistance Level | $0.86 | $14.15 |
| Average True Range (ATR) | 0.05 | 1.23 |
| MACD | -0.01 | 0.27 |
| Stochastic Oscillator | 16.00 | 62.23 |
Price Performance
Historical ComparisonAbout FSP Franklin Street Properties Corp.
Franklin Street Properties Corp is a real estate investment trust. The company is focused on commercial real estate investments in office markets and currently operate in only one segment: real estate operations. The principal revenue sources for its real estate operations include rental income from real estate leasing, property dispositions and fee income from asset/property management and development. The company provides asset management, property management, property accounting, investor and/or development services to its portfolio and Sponsored REIT through the company's subsidiaries.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.